Flurpiridaz (18F)

Last updated

Flurpiridaz (18F)
Flurpiridaz F18.svg
Clinical data
Trade names Flyrcado
Other namesNMB58, BMS-747158-02, flurpiridaz F-18, flurpiridaz F 18 [1] (USAN US)
AHFS/Drugs.com Flyrcado
License data
Routes of
administration 		Intravenous
ATC code
  • None
Legal status
Legal status
Identifiers
  • 2-tert-butyl-4-chloro-5-({4-[(2- [18F]fluoroethoxy)methyl]phenyl}methoxy)pyridazin-3(2H)-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C18H22Cl[18F]N2O3 [2]
Molar mass 367.8 [2]
3D model (JSmol)
  • CC(C)(C)N1N=CC(OCC2=CC=C(COCC[18F])C=C2)=C(Cl)C1=O
  • InChI=1S/C18H22ClFN2O3/c1-18(2,3)22-17(23)16(19)15(10-21-22)25-12-14-6-4-13(5-7-14)11-24-9-8-20/h4-7,10H,8-9,11-12H2,1-3H3/i20-1
  • Key:RMXZKEPDYBTFOS-LRFGSCOBSA-N

Flurpiridaz (18F), sold under the brand name Flyrcado, is a cyclotron-produced radioactive diagnostic agent for use with positron emission tomography (PET) myocardial perfusion imaging under rest or stress (pharmacologic or exercise). [3] Flurpiridaz (18F) It is given by intravenous injection. [3]

Contents

The most common adverse reactions include dyspnea (shortness of breath), headache, angina pectoris (severe pain in the chest), chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia (irregular heartbeat). [3]

Flurpiridaz (18F) was approved for medical use in the United States in September 2024. [3] [4] [5] [6]

Medical uses

Flurpiridaz (18F) is indicated for positron emission tomography myocardial perfusion imaging under rest or stress (pharmacologic or exercise) in adults with known or suspected coronary artery disease to evaluate for myocardial ischemia and infarction. [2] [3]

Adverse effects

Before administering, exercise and stress testing with adenosine should be performed, since elevated values might cause following side effects: [7]

Pharmacology

Mechanism of action

Flurpiridaz's structure can be divided into two parts: [7]

The radioactive signal is proportional to the blood flow; therefore, the healthy tissue is more radioactive than infarcted one. [8] It is partially selective towards the left ventricle than the right ventricle. [9] Moreover, mitochondrial uptake of the drug is dependent on mitochondrial membrane potential, which explains its mechanism of action. [10]

Pharmacokinetics

Flurpiridaz (18F) has peak blood radioactivity at 2.3 minutes after administration, followed by a rise and plateau. Distribution of this radiopharmaceutical is complex, as it transfuses into the liver (13%), kidneys (9%), brain (8%) and epicardium (3%, radioactivity retains for 1 hour after administration). Full clearance is achieved within 48 hours. Only metabolites of flurpiridaz are excreted, mainly in urine and feces. [7] Flurpiridaz metabolises into many different polar metabolites. [7]

There are no differences in pharmacocinetics in different groups according to age, sex, body mass index (BMI), diabetic status, Clid Pugh A hepatic impariment and renal impairment at eGFR≥19-89 mL/min). [7]

Chemistry

Radiation characteristics

Flurpiridaz (18F) has a halflife of 109.8 minutes and the main photons useful for imagin are those resulted from gamma decay through interaction of the positron with an electron. [7]

Fluorine-18 emission characteristics
Radioactive emission type% of disintegrationMean energy of decay (keV)
positron (β+)96.7249.8
gamma193.5511

Fluorine-18 decay characteristics were determined as follows: [7]

Decay characteristics of fluorine-18
ParameterValue
air-kerma rate constant3.74·10−17 Gy·m2/(Bq·s)
specific gamma-ray constant5.7 R/(hr·mCi) at 1 cm
first half-value thickness of lead6 mm

Effective dose at rest and adenosine-induced pharmacologic stress is equal to 0.019 mSv/MBq, and under exercise-induced stress – 0.016 mSv/MBq. Whole-body effective dose is described as follows:

Whole-body radiation dose
ConditionMaximal activity (MBq)Effective dose (mSv)Absorbed dose (mGy) in epicardium
Rest1112.15.3
Pharmacological stress2414.622
Exercise stress3255.314

Synthesis

Flupiridaz (18F) synthesis Flupiridaz (18F) synthesis.png
Flupiridaz (18F) synthesis

Methyl p-(hydroxymethyl)benzoate undergoes reaction with ethylene oxide with boron trifluoride etherate and dichloromethane to yield 2-hydroxyethyl ether. Then, the hydroxy group is substituted with tert-butyldimethylsilyl chloride (TMS-Cl) in dimethylformamide (DMF). Next, the ester is reduced into an according alcohol using lithium aluminium hydride (LAH) in tetrahydrofuran. The newly created hydroxy moiety undergoes addition with 2-tert-butyl-4-chloro-5-hydroxy-pyridazin-3-one. The TBSO group is then substituted with a tosyl group with a two-step reaction using (1) tetra-n-buthylammonium fluoride (TBAF) in THF and (2) tosyl chloride in 4-dimethylaminopyridine (DMAP), triethylamine (TEA) and dichloromethane. To create the final radiolabelled radiopharmaceutical, potassium fluoride-18 is used. This step is performed using kryptofix, a phase-transfer catalyst, and acetonitrile. Kryptofix (5-decyl-4,7,13,16,21-pentaoxa-1,10-diazabicyclo[8.8.5]tricosane), a cryptand, increases the solubility of the fluoride ion in organic solvents (here, acetonitrile), by chelating it.

History

Flurpiridaz F-18 is a fluorine 18-labeled agent developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease. [12]

The efficacy and safety of flurpiridaz (18F) were evaluated in two prospective, multicenter, open-label clinical studies in adults with either suspected CAD (Study 1: NCT03354273) or known or suspected CAD (Study 2: NCT01347710). [3] Study 1 evaluated the sensitivity (ability to designate an imaged patient with disease as positive) and specificity (ability to designate an imaged patient without disease as negative) of flurpiridaz (18F) for the detection of significant CAD in subjects with suspected CAD who were scheduled for invasive coronary angiography (ICA). [3] Across three flurpiridaz (18F) imaging readers, estimates of sensitivity ranged from 74% to 89% and estimates of specificity ranged from 53% to 70% for CAD defined as at least 50% narrowing of an artery. [3]

Study 2 evaluated the sensitivity and specificity of flurpiridaz (18F) for the detection of significant CAD in subjects with known or suspected CAD who had ICA without intervention within 60 days prior to imaging or were scheduled for ICA. [3] Across three flurpiridaz (18F) imaging readers, estimates of sensitivity ranged from 63% to 77% and estimates of specificity ranged from 66% to 86% for CAD defined as at least 50% narrowing of an artery. [3]

Society and culture

Flurpiridaz (18F) was approved for medical use in the United States in September 2024. [2] [3] In the European Union, it is still undergoing a phase three clinical trial. [13]

Names

Flurpiridaz (18F) is the international nonproprietary name. [14]

References

  1. ↑ "Flurpiridaz F 18". AMA Finder. Retrieved 27 September 2024.
  2. 1 2 3 4 5 "Flyrcado- flurpiridaz f-18 injection". DailyMed. 14 May 2025. Retrieved 24 June 2025.
  3. 1 2 3 4 5 6 7 8 9 10 11 "FDA approves imaging drug for evaluation of myocardial ischemia". U.S. Food and Drug Administration (FDA). 27 September 2024. Retrieved 27 September 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  4. ↑ "Drug Approval Package: Flyrcado Injection". U.S. Food and Drug Administration (FDA). 25 October 2024. Archived from the original on 30 March 2025. Retrieved 21 January 2025.
  5. ↑ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration. 1 October 2024. Archived from the original on 19 April 2024. Retrieved 8 November 2024.
  6. ↑ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
  7. 1 2 3 4 5 6 7 "FLYRCADO (flurpiridaz F 18) injection, for intravenous use" (PDF). Highlights of Prescribing Information. GE Health Care. Retrieved 20 July 2025.
  8. ↑ Higuchi T, Nekolla SG, Huisman MM, Reder S, Poethko T, Yu M, et al. (October 2008). "A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats". Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49 (10). Society of Nuclear Medicine: 1715–1722. doi:10.2967/jnumed.108.053967. eISSN   2159-662X. PMID   18794259.
  9. ↑ Barca C, Strunk M, Ross T, Bengel F, Thackeray J (1 June 2023). "Estimation of total body perfusion using [18F]Flurpiridaz in healthy mice and after myocardial infarction". Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 64 (supplement 1): P641. ISSN   0161-5505.
  10. ↑ Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, et al. (May 2009). "Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model". Circulation. 119 (17): 2333–2342. doi: 10.1161/CIRCULATIONAHA.108.797761 . PMID   19380625.
  11. ↑ Ahmed H, Haider A, Gisler L, Schibli R, Gebhard C, Ametamey SM (17 June 2020). "[ 18 F]Flurpiridaz: Facile and Improved Precursor Synthesis for this Next-Generation Cardiac Positron Emission Tomography Imaging Agent" . ChemMedChem. 15 (12): 1040–1043. doi:10.1002/cmdc.202000085. ISSN   1860-7179. PMID   32324949.
  12. ↑ "Flurpiridaz F-18". Inxight Drugs. Retrieved 27 September 2024.
  13. ↑ Clinical trial number NCT03354273 for "An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)" at ClinicalTrials.gov
  14. ↑ World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 65". WHO Drug Information. 25 (1). hdl: 10665/74623 .

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.